Security key
12529R107
C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CCCC)
CUSIP: 12529R107
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 79,828,313
- Total 13F value
- $152,468,758
- Share change
- +27,509,196
- Put/Call ratio
- 72%
- SEC-reported price per share
- $1.91
- Number of holders
- 101
- Value change
- +$51,887,612
- Number of buys
- 66
- Number of sells
- 35
- Shares outstanding
- 110,144,928
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
101
Top holders
10
CCCC full security history
Ownership snapshot
Full 13F holder table
C4 Therapeutics, Inc. SEC filings
C4 Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CCCC - C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Soleus Capital Master Fun...
Disclosed value leader
Soleus Capital Master Fun...
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
Lead comparable stake: 10%
13D/G row: Soleus Capital Master Fund, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Soleus Capital Master Fund, L.P. leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Soleus Capital Master Fund, L.P.'s linked filing trail.
Comparable ownership
Top 5
Soleus Capital Master Fund, L.P.
10%
WASATCH ADVISORS LP
6.8%
Bain Capital Life Sciences Fund I...
6.2%
ORBIMED ADVISORS LLC
1%
Lynx1 Capital Management LP
6.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. |
13D/G
|
10%
|
$19,791,153
10,361,860 shares
|
$0 | 31 Dec 2025 |
| WASATCH ADVISORS LP |
13D/G
13F
Company
|
6.8%
|
$10,773,085
4,852,741 shares
|
-$5,817,712 | 30 Sep 2025 |
| Bain Capital Life Sciences Fund II, L.P. |
13D/G
BCLS II Equity Opportunities, LP
|
6.2%
|
$13,453,200
6,060,000 shares
|
$0 | 17 Oct 2025 |
| ORBIMED ADVISORS LLC |
13F
13D/G
Company · OrbiMed Capital LLC
|
1%
from 13D/G
|
$11,622,024
5,235,146 shares
|
— | 30 Sep 2025 |
| Lynx1 Capital Management LP |
13F
Company
|
6.4%
|
$15,757,855
7,098,133 shares
|
— | 30 Sep 2025 |
| Soleus Capital Management, L.P. |
13F
Company
|
6.4%
|
$15,659,751
7,053,942 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
101
Shares
79,828,313
Rows available
101
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
96
Q4 2025 holders
101
Holder diff
5
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|